CMPI: I read each day new theories about how a new particle "may" revolutionize the progress of overcoming stumbling blocks holding back effectiveness of previous drug strategies...wonder what data point made it compelling to offer almost 4 times previous share price?
The REGN-CMPI deal has the second-highest premium among all biotech buyouts since 2008 with a deal value >=$200M, trailing only AGN-TBRA (#msg-168586536).
On the other hand, CMPI’s closing price yesterday was down 81% from its 2020 IPO (#msg-157450928), so even the 336% premium being paid by REGN amounts to a substantial discount from the IPO price.
News 
Market Data 
Discover 
